A significant percentage of patients infected with HIV-1 experience only suboptimal CD4 cell recovery while treated with combination therapy (cART). It is still unclear whether viral properties such as cell tropism play a major role in this incomplete immune response. This study therefore intended to follow the tropism evolution of the HIV-1 envelope during periods of suppressive cART.
Introduction
Whereas it is well established that a sustained CD4 recovery is a key determinant of the success of therapy for HIV infection, much less is known about the role of viral properties during disease progression or immunological recovery phases of the infection.
At the molecular level, successful HIV infection critically depends on high-affinity binding of the virus to cellular CD4 and a chemokine receptor serving as a viral coreceptor. Prior to cell entry, conformational changes in the HIV envelope enable an interaction of variable loop 3 (V3) and the chemokine receptor CCR5 (R5) or CXCR4 (X4) [1] . In this interaction, the virus does not have a "free choice" between these two receptors; key determinants, mainly located in V3, dictate which chemokine receptor can be bound by a given viral isolate.
Numerous reports have shown that, early after infection, most HIV-1 strains use R5 (up to 85% of cases). Accordingly, X4-tropic viral isolates remain rare early after infection and are more often isolated at later disease stages [2] [3] [4] [5] . Only for subtype D has a greater percentage of X4-using variants throughout the disease course been reported [6] . The drivers of a "tropism switch" from R5 to X4 in up to 50% of patients are not well understood.
Nevertheless, earlier reports have established that HIV-1 infections utilizing X4 are associated with an accelerated disease progression and a more rapid decline of CD4 cell counts [7] [8] [9] , and in advanced disease situations viruses may be less readily neutralized by host immune surveillance [10] . However, whether X4 tropism is a cause or a consequence of an impaired immune response is still under debate. Although there are currently no clinically available entry inhibitors that target X4, a better understanding of the mechanisms that drive viral infection via X4 is of central relevance. Reliable genotypic tropism tests have been established for identifying the viral tropism and to dissect mixed virus populations [11] [12] [13] .
A reported paradox is that a subset of HIV-infected patients, although fully responding to antiretroviral treatment, may experience delayed and suboptimal CD4 cell recovery. In 2005, Kaufmann et al. [14] studied such profiles of CD4 cell recovery over time during periods of fully suppressive combination antiretroviral therapy (cART). They assigned patients to an "immunologically responding" or a "non-responding" group. The only significant correlates in that study were "low baseline CD4 T-cell counts" and "age at time of infection". Considering that in other studies X4 tropism was associated with poorer disease outcome [7] , we hypothesized that CD4 cell response to cART might be directly affected by properties of the viral envelope (Env) protein. We set out to assess viral tropism at the time of cART initiation and after extended periods of successful therapy. Tropism was analysed for a subpopulation of the patients included in the above-mentioned study, i.e. for virus from patients with sustained vs. transient or poor immune recovery. In addition to this aspect of CD4 recovery, our study also followed viral tropism over time, comparing pre-cART samples with those obtained after several years of therapy. For this analysis, free plasma virus as well as proviral DNA from peripheral blood mononuclear cells (PBMCs) were examined. 
Methods

Ethics statement
Sample selection and tropism testing
Plasma and cell samples from 88 patients in the Swiss HIV Cohort Study were included in this study. Samples were grouped, according to the patients' absolute difference in CD4 count (DCD4) after 5 years on cART, into "responders" (n = 44) with a DCD4 > 400 cells/lL [median 579 cells/lL; interquartile range (IQR) 499À705 CD4 cells/lL] and "incomplete responders" (n = 44) with a DCD4 that remained < 400 cells/lL (median 235 cells/lL; IQR 192À308 cells/ lL). Tropism analysis was performed on plasma and on PBMCs near the time of cART initiation, and 5 years later on PBMCs. For tropism determination, two methods were available: Geno2Pheno (G2P; Max-Planck-Institute, Saarbr€ ucken, Germany) and XTrack (InPheno AG, Basel, Switzerland). For all patients, the expected rapid viral load (VL) decline after cART initiation was noted. VLs stayed below 50 HIV-1 RNA copies/mL with no viral rebound for the entire study period (VL was routinely measured every quarter). cART was defined as any appropriate combination of at least three antiretroviral drugs, either two nucleoside reverse transcriptase inhibitors (NRTIs) combined with one or two protease inhibitors or two NRTIs combined with one nonnucleoside reverse transcriptase inhibitor (NNRTI). None of the patients ever received R5 antagonists for therapy.
RNA and DNA extraction was performed with the chemagen Prepito (Perkin Elmer, Baesweiler, Germany) using the NA Body Fluid Kit (Perkin Elmer) according to the manufacturer's protocol. For amplification of the V3 loop, a validated in-house protocol was used. In brief, RNA was reverse transcribed using the Affinity Script One-Step RT-PCR Kit (Agilent Technologies, Basel, Switzerland). The product was cleaned with Illustra Exostar 1-Step (GE Healthcare, Glattbrugg, Switzerland), and nested polymerase chain reaction (PCR) was performed using PfuUltra II Fusion HS (Agilent Technologies). PCR products were sequenced on an ABI 3130 Genetic Analyzer (Fisher Scientific, Reinach, Switzerland), and tropism was assigned using the online tool G2P Tropism version 2.5 (Max-PlanckInstitut, Saarbrü cken, Germany) with a false positive rate (FPR) cut-off value of either 5% or 10%. For tropism assessment with XTrack, the kit protocol was followed.
Categorical data were compared by means of a v 2 test, whereas continuous data were compared using a MannÀWhitneyÀWilcoxon test.
Results
Patient characteristics
The patient population (n = 88) had a mean age of 54.5 years AE 10.9 years, 76% were male, 90% were white, 49% were men who have sex with men (MSM), the mean duration of infection was 18.7 years AE 4.7 years [15] , and 76% of the patients had started cART prior to the year 2000. The baseline median CD4 count was 174 cells/ lL, the baseline CD8 count was 787 cells/lL, and the baseline VL was 4.97 log 10 copies/mL. Based on analysis at the follow-up time-point, 21% of the patients (17 of 81 patients; samples from seven patients could not be analysed) had a D32 heterozygous genotype. Baseline characteristics are summarized in Table 1 .
In the incomplete responder group, overall, patients had initiated cART at a lower median CD4 count of 139 cells/lL vs. 220 cells/lL in the responder group (P = 0.039). It was therefore crucial to rule out a CD4-based bias in our findings. Therefore, a subanalysis (n = 38) of incomplete responders with a high CD4 count nadir vs. complete responders with a low CD4 count nadir was performed, and confirmed that a lower CD4 count nadir was not the primary cause of incomplete response (P = 0.073).
The median CD8 count at baseline for incomplete responders was 861 vs. 764 cells/lL for complete responders (P = 0.78), and the median VL was 5.02 vs. 4.82 log 10 copies/mL, respectively (P = 0.152).
Demographic characteristics revealed a longer, but not significantly significant, duration of infection [15] for incomplete responders, at 19.6 years vs. 17.8 years for complete responders (P = 0.106). The occurrence of the D32 heterozygous genotype was similar in the two groups (ten and seven cases, respectively; P = 0.446). There was no statistically significant difference in the first-line regimen between the two patient groups (data not shown), and for 90% of patients the primary regimen consisted of a protease inhibitor with an NRTI backbone. Data are presented as n (%) or median (interquartile range), unless otherwise indicated. Categorical data were compared by means of a v 2 test, whereas continuous data were compared using the MannÀWhitneyÀWilcoxon test. One patient in the incomplete responder group is missing because no data were available. . CDC, Centers for Disease Control and Prevention; HET, heterosexual; IDU, injecting drug use; MSM, men who have sex with men; SD, standard deviation.
Sample analysis
Corresponding baseline data sets for plasma virus (PL) and provirus (PBMCs) were available for 39 patients. Tropism analysis with G2P was largely concordant for virus and provirus at baseline in 90% of patients (35 of 39 patients).
A total of 88 baseline profiles were available for comparison. Overall, 44 were responders and 44 were incomplete responders according to the patients' DCD4 count after 5 years of follow-up. Eighty-one samples of the 88 (92%) had concordant results between G2P and XTrack. In order to follow the possible evolution of the viral tropism, proviral data from PBMCs at baseline (BL-PBMC) were compared with PBMC data at follow-up (5Y-PBMC), where 50 sample sets were available. For comparison of the 5Y-PBMC samples with their corresponding baseline plasma samples (BL-Plasma), 61 sample sets were available.
CD4 cell response: correlating baseline tropism with immunological outcome
The mean time span between baseline analysis and timepoint of follow-up was 5.2 years AE 0.6 years. For 84 patients, tropism assignment was successful using the online tool G2P. The FPR cut-off was set to 5%. For four patients, G2P yielded no result because of the presence of a mixed virus population. G2P predicted 69 (82.1%) patients to carry an R5-tropic virus and 15 (17.9%) to carry an X4-tropic virus, considering that 88% of samples had subtype B determined by G2P. Sixty per cent (nine of 15) of patients with X4-tropic viruses and 46.4% (32 of 69) with R5-tropic viruses were in the incomplete responder group (P = 0.339). Data are shown in Table 2 .
Similar results were obtained with the hybridizationbased XTrack system. In the incomplete responder group, 42% (21 of 50) of the patients harboured R5-tropic viruses, 64% (16 of 25) a mixed virus population, and 53.8% (seven of 13) X4-tropic viruses (P = 0.190), as shown in Table 2 . Disregarding the 25 patients with mixed virus populations, G2P and XTrack yielded concordant results in 88.9% of patients (56 of 63).
Tropism evolution in provirus at baseline and after therapy
For the comparison of proviral DNA in PBMCs at baseline and 5 years later (BL-PBMC/5Y-PBMC), a complete data set (G2P and XTrack) was available for 50 patients. Five patients had no G2P result because of mixed viral sequences and one had no Xtrack result because of inconclusive results. The vast majority of patients (86.7%; 39 of 45 analysed samples) carried R5-tropic virus at baseline. Thirty-three of these 39 patients (84.6%) still had R5-tropic virus at follow-up, and in the remaining six patients the tropism had changed to X4 use. Of the six patients with X4-tropic virus at baseline, four (66.7%) had changed to R5 tropism at follow-up. G2P data are summarized in Fig. 1a . The median (mean in parentheses) FPR value for the incomplete responder group at baseline was 40.3 (37.33) vs. 43.8 (43.02) (P = 0.424) at followup, whereas it was 46.8 (45.35) at baseline vs. 27.5 (36.78) (P = 0.188) at follow-up in the responder group.
The XTrack analysis was particularly useful in examining mixed virus populations. Among the 28 patients with initially R5-tropic HIV, four (14.3%) presented with a mixed virus population at follow-up. Among the nine patients with a mixed population at baseline, the mixed tropism remained stable in two cases (22.2%) after 5 years. A tropism change to R5 occurred in four (44.5%) patients, and in three (33.3%) cases the later samples revealed solely X4-tropic virus. For the 12 patients with X4-tropic virus at baseline, only one (8.3%) changed to a mixed tropism. Data are summarized in Fig. 2a .
Tropism evolution in plasma at baseline and provirus after treatment
In the initial data set, 61 patients had a G2P and XTrack baseline plasma tropism result available as well as a corresponding follow-up proviral tropism result from PBMCs. Six had no G2P result because of mixed viral sequences, and one had no Xtrack result because of inconclusive results. At baseline, we identified R5-tropic viruses in 47 (85.5%) of the remaining 55 patient samples, of which 40 (85.1%) were still R5-tropic at followup. Among the eight X4-tropic virus samples at baseline, the tropism had changed in six (75%) patients to R5 at follow-up. G2P data are summarized in Fig. 1b . In this setting, at baseline the median (mean in parentheses) FPR value for the incomplete responder group was 31.5 (34.86) vs. 43.8 (43.02) (P = 0.208) at follow-up, whereas it was 29.2 (35.68) at baseline vs. 27.5 (36.78) (P = 0.996) at follow-up in the responder group. When XTrack was used to examine mixed virus populations among the 36 (60%) R5-tropic samples at baseline, four (11.1%) were found to have changed to a mixed population. For 17 patients with a mixed virus population at baseline, HIV changed to become R5-tropic in nine cases (52.9%) and to become X4-tropic in two cases (11.8%), and in six cases (35.3%) the viral tropism remained mixed. Among the seven patients with an X4-tropic virus at baseline, one (14.3%) had a change to a mixed population. The results are shown in Fig. 2b .
Considering the excellent concordance observed between baseline plasma and PBMC samples (in 90% of cases), we grouped the samples changing from an X4 tropism at baseline to R5 at follow-up, regardless of their origin, plasma or PBMCs. Thus, overall 71.4% (10 of 14) of all patients with an X4 tropism at baseline had changed to R5 at follow-up in the G2P analysis.
Analysis of viral envelopes with tropism switch
For the majority of X4-tropic viruses that presented with an R5 tropism determination after 5 years, several random nucleotide changes in the V3 loop sequence were observed. In contrast, for most R5-tropic viruses switching tropism to X4 use, a single nucleotide change was sufficient to yield the X4 tropism. The most frequent transitions were G to A transitions, which were typically associated with an amino acid change, mostly from serine, glycine or glutamine to arginine. Those occurred at positions 11, 24 or 25 of the V3 loop. Also, about half of the affected viruses lost at least one potential N-linked glycosylation site. Analysis with HYPERMUT 2.0 (www.hiv.lanl.gov) did not detect an accumulation of hypermutations in any of the sequences.
Discussion
Impaired CD4 cell recovery despite successful cART has previously been described, largely in the absence of known plausible causes [14] . This study addressed whether a tropism determination prior to cART initiation would be able to predict a later poorer immune response. We observed that 60% of all patients with X4-tropic viruses at therapy initiation experienced only partial immune recovery during the following 5 years (DCD4 < 400 cells/lL). In addition, analysis of proviral HIV sequences at this later time-point during therapy revealed that, in a majority of patients, the tropism determination "changed" from X4-tropic at baseline to R5. In contrast, most patients with R5 tropism at baseline retained R5-tropic viruses.
Although X4 to R5 changes were so much more frequent, we further observed that a single nucleotide change was typically sufficient for the change to X4 tropism, whereas a tropism change from X4 to R5 required several point mutations. This lends further strong support to the notion that tropism changes did not occur as a consequence of spontaneous, isolated mutations. It is compatible with the concept that R5-tropic variants in this study emerged from minorities (mixed virus populations) already pre-existing in the patient.
Of note, most single nucleotide changes occurred at position 11, 24 or 25 of the V3 loop, mostly as G to A transitions. It has previously been reported that apolipoprotein B mRNA-editing enzyme, catalytic polypeptide 3G/F (APO-BEC3) triggers such G to A mutations and might thus be directly responsible for or involved in viral tropism changes [16] . Moreover, in half of the patients, a change to X4 tropism coincided with the loss of a potential N-linked glycosylation site. This is in good concordance with earlier findings that glycosylation patterns change during the disease course, usually with a loss of sites in late virus isolates and a correlation with X4 tropism [17] [18] [19] .
Based on the data obtained in this study, it appears unlikely that a D32 genotype that would potentially favour X4 tropism impacted our findings. Patients identified as having D32 heterozygosity (21% of all samples) were equally distributed between the two groups, and so the D32 genotype had no influence on viral tropism under therapy. Overall, the D32 prevalence did not differ from that found in other studies in Caucasian populations [20] .
Although the small sample size in this study imposes certain limitations, a clear trend was seen (1) for the association of X4 tropism with CD4 deterioration under cART and (2) towards a strong reduction of X4-tropic variants under successful therapy. A possible confounder in our study was the generally lower baseline CD4 cell count in the nonresponder group. Yet the two groups overlapped significantly, and some patients with a low baseline CD4 count of < 150 cells/lL belonged to the responders, whereas others with a baseline CD4 count of > 150 cells/lL had a DCD4 of < 400 cells/lL.
Alternatively to this being suggestive of a poor prognosis for CD4 recovery, this finding might be an indicator of higher levels of inflammation and immune stimulation by X4-tropic HIV. It has been reported that such activation can favour the elimination of cells infected with X4-tropic HIV in vivo [21] .
The finding that the majority (10 of 14) of viruses with X4 tropism at baseline had changed to R5-tropic viruses during the period of successful cART was somewhat surprising and argues against the driving role of persistently replicating X4-tropic HIV in CD4 cell deterioration. It rather provides evidence for a greater proviral stability of R5-tropic HIV during suppressive therapy and may therefore suggest that R5 variants need to be more effectively targeted by therapy.
The intriguing observation that during suppressive cART X4-tropic (proviral) HIV appears to decrease over time invites us to hypothesize that, under successful cART and stable CD4 cell recovery, the immune system manages to preferentially reduce and potentially eliminate X4-tropic HIV or HIV-infected cells.
Further support for this hypothesis comes from the reports of other authors that superior immunological recognition of X4-tropic HIV is associated with tropismsensitive overstimulation of the immune system and associated CD4 cell death [21] . Other studies suggest furthermore that antiretroviral therapy itself could lead to a diminution of X4-tropic HIV-1 [22, 23] . Those data are also in line with observations from the Maraviroc versus Optimized Therapy in Viremic Antiretroviral TreatmentExperienced Patients (MOTIVATE) studies of the R5 antagonist maraviroc in patients on salvage regimens, where the majority of these heavily pretreated patients presented at baseline with R5-tropic virus despite long durations of infection and therapy [24] . A striking finding in the same studies was that, upon discontinuation of maraviroc, X4-tropic virus variants rapidly disappeared with the prompt re-emergence of R5-tropic HIV [25] , similar to emerging virus in patients failing first-line cART [26] .
In line with some [22, 23] but in contrast to other reports [27] , we observed in our study a reduction of X4-tropic variants during cART, and cannot support claims of an overrepresentation of X4-tropic virus in proviral samples compared with plasma. This is in agreement with other reports which, however, concluded that proviral tropism testing should not be used because of an assumed false underrepresentation of X4-tropic variants in the proviral reservoir [28] . Yet our observations are fully in line with these data as they also demonstrated over time a higher proportion of R5-tropic virus sequences in the cellular compartment. Here, we provide evidence that the lower representation is indeed real and rather reflects an immunological shift during cART and a loss of cells harbouring X4-tropic viruses.
It will therefore be of great interest to further investigate whether a tropism-dependent mechanism of virus control can consistently be exerted during cART. Should it be possible to preferentially control X4-tropic HIV variants by strengthening immune functions, for example under maximal pressure of combination therapy and while CD4 cell function is still intact (> 500 cells/lL), R5-coreceptor antagonists might find a new role in therapy [21] .
Further studies with larger sample sizes and more potent molecular tools, such as next generation sequencing (NGS), will be needed to confirm our results clinically, but these observations could have a bearing on new strategies for controlling HIV in immunologically active body compartments.
